Toshinari Ohara, Ph.D., Chief Executive Officer

Toshinari Ohara is currently the Chief Executive Officer at Sekisui XenoTech. Toshi received a Ph.D. in Pharmaceutical Sciences from Nagoya City University in 1991. Toshi was previously part of the management team at XenoTech from 2009 to 2013 before returning to Sekisui Medical Co. to serve as the Head of the R&D division at the ADME & Tox Research Institute. Most recently, Toshi served as the General Manager of Business Planning Department for Sekisui's Drug Development Solutions Division.

Joanna Barbara, Ph.D., Vice President, Scientific Operations

Joanna Barbara currently serves as Vice President of Scientific Operations at Sekisui XenoTech. Joanna obtained her Ph.D. in Analytical Chemistry from the University of Florida. She joined Sekisui XenoTech in 2007. In that time, Joanna has served in Mass Spectrometry Specialist roles, as the Division Director of Analytical Services and Division Director of Scientific Operations at Sekisui XenoTech. Dr. Barbara also serves as an Adjunct Graduate Professor of Pharmaceutical Sciences for the College of Pharmacy at the University of Missouri – Kansas City. She has authored or coauthored numerous scientific posters and papers, and has represented Sekisui XenoTech as an invited speaker at various analytical and drug metabolism conferences. Joanna is quality-oriented with extensive experience in DMPK, regulatory compliance and process and project management. As Vice President of Scientific Operations, Dr. Barbara is responsible for the development, design, operation, and improvement of Sekisui XenoTech's Scientific Division.

Brian Ogilvie, Ph.D., Vice President, Scientific Consulting

Brian Ogilvie currently serves as Vice President of Scientific Consulting at Sekisui XenoTech. Brian obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. He joined XenoTech in 1997. From 1999 to 2006 Dr. Ogilvie was the head of the CYP Inhibition Department at Sekisui XenoTech. Brian is an author or coauthor on over 50 scientific posters, peer-reviewed publications or book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented the company as an invited speaker at various drug metabolism conferences. In April 2006, Brian became a member of the Sekisui XenoTech Consulting Department, in which he participates in drug-drug interaction-related R&D projects and authoring various publications, and also writes expert opinions for consulting clients. As Vice President of Scientific Consulting, Dr. Ogilvie is additionally involved in quality management and strategic planning for the company in scientifically relevant areas.

Angela Kreps, Vice President, Commercial Operations

Angela joined Sekisui XenoTech in 2015 after serving 10 years as the president and CEO of the Kansas Bioscience Organization where she was instrumental in regional and national bioscience initiatives for funding, research, and education. Angela leads the Commercial Operations division which includes Sales, Marketing, and Customer Service. In her first year with Sekisui XenoTech, Angela’s team exceeded all revenue targets, setting company records for product sales and customer service. Named one of Kansas City’s Most Influential Women in 2008, Angela has filled executive and producer roles in multiple industries including bioscience, non-profit, tax compliance, and financial services, earing multiple President’s Clubs, Top Manager awards, and individual career achievements. Outside of work Angela enjoys golf and donates time to a number of Boards of Directors and Advisory Boards. Angela graduated from Kansas State University with a Bachelor of Science degree and lives in Kansas City with her husband and daughters.

Maciej Czerwinski, Ph.D., Division Director, Consulting

Maciej Czerwinski currently serves as Director of Consulting at Sekisui XenoTech. Maciej received his PhD from the University of Maryland at Baltimore Medical School in the Department of Pathology. He conducted his doctoral thesis research in the Laboratory of Dr. Frank Gonzalez at National Cancer Institute in Bethesda, followed by a post-doc at the Department of Pharmaceutics, University of Washington in Seattle. He has been with Sekisui XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Maciej designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs. Dr. Czerwinski is also the inventor of XenoTech’s CryostaX single-freeze pooled hepatocytes.

Zell Woodworth, Division Director, Products

Zell Woodworth currently serves as the Director of Products at Sekisui XenoTech. Zell holds B.Sc. Degrees in Biology and Chemistry from Olivet Nazarene University in Illinois. He began his career with XenoTech in 1996 and has over 20 years of experience in the development, production, and distribution of tissue-derived in vitro experimental models essential in drug candidate screening, drug-drug interaction investigations, and drug safety. Zell’s current role is the management of raw material procurement, development, production, and quality control of over 350 biological products utilized in pharmaceutical research in over 25 countries. Zell continues to provide technical support, product workshops, and in vitro test system support throughout the US, Europe, Japan, and India.